<SEC-DOCUMENT>0001213900-24-046419.txt : 20240524
<SEC-HEADER>0001213900-24-046419.hdr.sgml : 20240524
<ACCEPTANCE-DATETIME>20240524080017
ACCESSION NUMBER:		0001213900-24-046419
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		17
CONFORMED PERIOD OF REPORT:	20240524
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20240524
DATE AS OF CHANGE:		20240524

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ABVC BIOPHARMA, INC.
		CENTRAL INDEX KEY:			0001173313
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				260014658
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-40700
		FILM NUMBER:		24980855

	BUSINESS ADDRESS:	
		STREET 1:		44370 OLD WARM SPRINGS BLVD.
		CITY:			FREMONT
		STATE:			CA
		ZIP:			94538
		BUSINESS PHONE:		510-668-0881

	MAIL ADDRESS:	
		STREET 1:		44370 OLD WARM SPRINGS BLVD.
		CITY:			FREMONT
		STATE:			CA
		ZIP:			94538

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	American BriVision (Holding) Corp
		DATE OF NAME CHANGE:	20160111

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	METU BRANDS, INC.
		DATE OF NAME CHANGE:	20150908

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ECOLOGY COATINGS, INC.
		DATE OF NAME CHANGE:	20080821
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>ea0206790-8k_abvcbio.htm
<DESCRIPTION>CURRENT REPORT
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:us-roles="http://fasb.org/us-roles/2023" xmlns:country="http://xbrl.sec.gov/country/2023" xmlns:srt="http://fasb.org/srt/2023" xmlns:ABVC="http://abvcpharma.com/20240524">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html"/>
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02C_US%2DGAAP%2D2023 -->
<!-- Field: Set; Name: xdx; ID: xdx_037_ABVC_abvcpharma.com_20240524 -->
<!-- Field: Set; Name: xdx; ID: xdx_048_20240524_20240524 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DEntityCentralIndexKey_0001173313 -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="AsOf2024-05-24" id="Fact000003" name="dei:AmendmentFlag">false</ix:nonNumeric>
  <ix:nonNumeric contextRef="AsOf2024-05-24" id="Fact000004" name="dei:EntityCentralIndexKey">0001173313</ix:nonNumeric>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="abvc-20240524.xsd" xlink:type="simple"/>
  </ix:references>
 <ix:resources>
    <xbrli:context id="AsOf2024-05-24">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-05-24</xbrli:startDate>
        <xbrli:endDate>2024-05-24</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p>

<!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 2pt solid; border-bottom: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>UNITED STATES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>SECURITIES AND EXCHANGE COMMISSION</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>Washington, DC 20549</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>FORM <span id="xdx_90C_edei--DocumentType_c20240524__20240524_zhxGlD01tGNe"><ix:nonNumeric contextRef="AsOf2024-05-24" id="Fact000009" name="dei:DocumentType">8-K</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>CURRENT REPORT</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Pursuant to Section 13 or 15(d) of the Securities
Exchange Act of 1934</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Date of Report (Date of earliest event reported):
<span id="xdx_904_edei--DocumentPeriodEndDate_c20240524__20240524_zle0FOYUTnma"><ix:nonNumeric contextRef="AsOf2024-05-24" format="ixt:datemonthdayyearen" id="Fact000010" name="dei:DocumentPeriodEndDate">May 24, 2024</ix:nonNumeric></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b><span id="xdx_900_edei--EntityRegistrantName_c20240524__20240524_zvY7Fzerkonk"><ix:nonNumeric contextRef="AsOf2024-05-24" id="Fact000011" name="dei:EntityRegistrantName">ABVC BIOPHARMA, INC.</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Exact name of registrant as specified in its charter)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="border-bottom: black 1.5pt solid; width: 32%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_907_edei--EntityIncorporationStateCountryCode_c20240524__20240524_zJQE6noSO6Hi"><ix:nonNumeric contextRef="AsOf2024-05-24" format="ixt-sec:stateprovnameen" id="Fact000012" name="dei:EntityIncorporationStateCountryCode">Nevada</ix:nonNumeric></span></b></span></td>
    <td style="width: 2%; text-align: center">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; width: 32%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_907_edei--EntityFileNumber_c20240524__20240524_zD00EbPmX4Hh"><ix:nonNumeric contextRef="AsOf2024-05-24" id="Fact000013" name="dei:EntityFileNumber">001-40700</ix:nonNumeric></span></b></span></td>
    <td style="width: 2%; text-align: center">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; width: 32%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_902_edei--EntityTaxIdentificationNumber_c20240524__20240524_zL8YORkUC0Ug"><ix:nonNumeric contextRef="AsOf2024-05-24" id="Fact000014" name="dei:EntityTaxIdentificationNumber">26-0014658</ix:nonNumeric></span></b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(State or other jurisdiction<br/>
of incorporation)</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Commission File Number)</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(IRS Employer<br/>
Identification No.)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="border-bottom: black 1.5pt solid; vertical-align: top; width: 49%">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_904_edei--EntityAddressAddressLine1_c20240524__20240524_zQPiIf8GTG06"><ix:nonNumeric contextRef="AsOf2024-05-24" id="Fact000015" name="dei:EntityAddressAddressLine1">44370 Old Warm Springs Blvd.</ix:nonNumeric></span></b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_90C_edei--EntityAddressCityOrTown_c20240524__20240524_zq0oB6FNRLUk"><ix:nonNumeric contextRef="AsOf2024-05-24" id="Fact000016" name="dei:EntityAddressCityOrTown">Fremont</ix:nonNumeric></span>, <span id="xdx_908_edei--EntityAddressStateOrProvince_c20240524__20240524_zSZaeSCMIdf8"><ix:nonNumeric contextRef="AsOf2024-05-24" id="Fact000017" name="dei:EntityAddressStateOrProvince">CA</ix:nonNumeric></span></b></p></td>
    <td style="vertical-align: top; width: 2%; text-align: center">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; vertical-align: bottom; width: 49%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_90F_edei--EntityAddressPostalZipCode_c20240524__20240524_z7TJofAh72Vc"><ix:nonNumeric contextRef="AsOf2024-05-24" id="Fact000018" name="dei:EntityAddressPostalZipCode">94538</ix:nonNumeric></span></b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Address of principal executive offices)</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Zip Code)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Registrant&#8217;s telephone number including area
code: <b>(<span id="xdx_904_edei--CityAreaCode_c20240524__20240524_zYzVYbcVYd84"><ix:nonNumeric contextRef="AsOf2024-05-24" id="Fact000019" name="dei:CityAreaCode">510</ix:nonNumeric></span>) <span id="xdx_905_edei--LocalPhoneNumber_c20240524__20240524_z3eHVHKRAMX1"><ix:nonNumeric contextRef="AsOf2024-05-24" id="Fact000020" name="dei:LocalPhoneNumber">668-0881</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Former name or former address, if changed since
last report)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Check the appropriate box below if the Form 8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_edei--WrittenCommunications_c20240524__20240524_zHTMFAmB6Xw7"><ix:nonNumeric contextRef="AsOf2024-05-24" format="ixt:booleanfalse" id="Fact000021" name="dei:WrittenCommunications">&#9744;</ix:nonNumeric></span></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_907_edei--SolicitingMaterial_c20240524__20240524_z6KLmpqJKJE"><ix:nonNumeric contextRef="AsOf2024-05-24" format="ixt:booleanfalse" id="Fact000022" name="dei:SolicitingMaterial">&#9744;</ix:nonNumeric></span></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_edei--PreCommencementTenderOffer_c20240524__20240524_zyxoQe4Id3q1"><ix:nonNumeric contextRef="AsOf2024-05-24" format="ixt:booleanfalse" id="Fact000023" name="dei:PreCommencementTenderOffer">&#9744;</ix:nonNumeric></span></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_edei--PreCommencementIssuerTenderOffer_c20240524__20240524_ziZ4jq2K5Iu3"><ix:nonNumeric contextRef="AsOf2024-05-24" format="ixt:booleanfalse" id="Fact000024" name="dei:PreCommencementIssuerTenderOffer">&#9744;</ix:nonNumeric></span></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Securities registered pursuant to Section 12(b) of the Act:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1.5pt solid; white-space: nowrap; width: 32%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Title of Each Class</b></span></td>
    <td style="white-space: nowrap; width: 2%; text-align: center">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; white-space: nowrap; width: 32%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Trading Symbol</b></span></td>
    <td style="white-space: nowrap; width: 2%; text-align: center">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; white-space: nowrap; width: 32%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name of each exchange on which registered</b></span></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_edei--Security12bTitle_c20240524__20240524_zBdBpI52ap31"><ix:nonNumeric contextRef="AsOf2024-05-24" id="Fact000025" name="dei:Security12bTitle">Common Stock, par value $0.001 per share</ix:nonNumeric></span></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_edei--TradingSymbol_c20240524__20240524_zWwoi9ihW7I6"><ix:nonNumeric contextRef="AsOf2024-05-24" id="Fact000026" name="dei:TradingSymbol">ABVC</ix:nonNumeric></span></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The <span id="xdx_908_edei--SecurityExchangeName_c20240524__20240524_z8GSmOCeDnm9"><ix:nonNumeric contextRef="AsOf2024-05-24" format="ixt-sec:exchnameen" id="Fact000027" name="dei:SecurityExchangeName">Nasdaq</ix:nonNumeric></span> Stock Market LLC</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant
is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (&#167;&#160;230.405 of this chapter) or Rule
12b-2 of the Securities Exchange Act of 1934 (&#167; 240.12b-2 of this chapter).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Emerging growth company <span id="xdx_90B_edei--EntityEmergingGrowthCompany_c20240524__20240524_zb5lzAwwJqe3"><ix:nonNumeric contextRef="AsOf2024-05-24" format="ixt:booleanfalse" id="Fact000028" name="dei:EntityEmergingGrowthCompany">&#9744;</ix:nonNumeric></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 1pt solid; border-bottom: Black 2pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Item 1.01 Entry into Material Definitive Agreements</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On May 23, 2024, the Company
entered into a definitive agreement with OncoX BioPharma, Inc., a private company registered in the British Virgin Islands (&#8220;<b>Oncox</b>&#8221;),
pursuant to which the Company will grant Oncox an exclusive right to develop and commercialize ABVC&#8217;s BLEX 404 single-herb botanical
drug extract from the dry fruit body of Maitake Mushroom (Grifola Frondosa) for treatment of Myelodysplastic Syndrome (the &#8220;<b>Licensed
Products</b>&#8221;), within a certain territory, specified as 50% of the Worldwide Markets for 20 years (the &#8220;<b>Oncox Agreement</b>&#8221;).
In consideration thereof, Oncox shall pay ABVC a total of $6,250,000 (or 1,250,000 Oncox shares valued at $5 per share<sup>1</sup>) 30
days after entering the Oncox Agreement, with an additional milestone payment of $625,000 in cash after OncoX&#8217;s next round of fundraising,
of which there can be no guarantee. Oncox may remit cash payments of at least $100,000 towards the licensing fees and deductible from
the second milestone payment; ABVC is also entitled to royalties of 5% of Net Sales, as defined in the Oncox Agreement, from the first
commercial sale of the Licensed Product in the noted territory, which remains uncertain. Oncox may use its revenue to fund the licensing
fees. Oncox entered into the same agreement with ABVC&#8217;s affiliate, Biolite, Inc.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">The
foregoing description of the agreements is not complete and is qualified in its entirety by reference to the full text of the agreements,
copies of which are attached as Exhibit 10.1 and Exhibit 10.2 to this Current Report on Form 8-K and incorporated herein by reference.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Neither this Current Report
on Form 8-K, nor any exhibit attached hereto, is an offer to sell or the solicitation of an offer to buy the Securities described herein.
Such disclosure does not constitute an offer to sell, or the solicitation of an offer to buy nor shall there be any sales of the Company&#8217;s
securities in any state in which such an offer, solicitation or sale would be unlawful. The securities mentioned herein have not been
registered under the United States Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration
or an applicable exemption from the registration requirements under the Securities Act and applicable state securities laws.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Item 9.01 Financial Statement and Exhibits
</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(d) Exhibits</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="border-bottom: black 1.5pt solid; vertical-align: top; width: 9%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exhibit No.</b></span></td>
    <td style="vertical-align: top; width: 1%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; vertical-align: bottom; width: 90%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Description</b></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ea020679001ex10-1_abvcbio.htm">Definitive License Agreement between the Company and OncoX BioPharma, Inc. May 23, 2024</a></span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.2</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ea020679001ex10-2_abvcbio.htm">Definitive License Agreement between Biolite, Inc. and OncoX BioPharma, Inc. dated May 23, 2024</a></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ea020679001ex99-1_abvcbio.htm">Press Release</a> </span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">104</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cover Page Interactive Data File, formatted in Inline XBRL</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0%"/>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>1</sup></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Price was determined through private negotiations between the parties; no third party valuation was completed.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></p>

<!-- Field: Page; Sequence: 2; Options: NewSection -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>SIGNATURE</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the requirements
of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ABVC BioPharma, Inc.</b></span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="width: 60%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">May 24, 2024</span></td>
    <td style="width: 4%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</span></td>
    <td style="border-bottom: black 1.5pt solid; width: 36%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Uttam Patil</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Uttam Patil</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">2</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p>

<!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- eJxFjU0KwjAQhU/QOwxZl5pG3XRpqSJWkSLiNtpRgm2mTOLfkbylsUUcBobhve89IWKxoLlpkOEwq0rYYds12iNUeEZGe8LgyJerDMKt8GKcZ219//7AnAKDgZkmSh2D0FvvxmGdgZyO1HikJiDTTKawXYvoq+dkz6ZG641uQNsatkwdG/SaX0PCTj/JUvvqq/bIzpDNIE3kIL9ByVTBhu76QXx1UJa5iOJ+IrFgunXBVTw92i8JRYNtqHMD/d/oAwJBSoU= -->
</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>ea020679001ex10-1_abvcbio.htm
<DESCRIPTION>DEFINITIVE LICENSE AGREEMENT BETWEEN THE COMPANY AND ONCOX BIOPHARMA, INC. MAY 23, 2024
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 10.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Definitive Licensing Agreement</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This Definitive Licensing Agreement (&ldquo;Agreement&rdquo;) is entered
into this May 23, 2024 (the &ldquo;Effective Date&rdquo;) by and between:</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">(1)</TD><TD STYLE="text-align: justify">ABVC BioPharma, Inc., a company registered in Nevada. (&ldquo;ABVC&rdquo;);
and</TD>
</TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">(2)</FONT></TD><TD STYLE="text-align: justify">OncoX BioPharma, Inc. (&ldquo;ONCOX&rdquo;), a company registered
in the British Virgin Islands.; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">ABVC and ONCOX shall be referred to
individually as a &ldquo;Party&rdquo; and collectively as the &ldquo;Parties&rdquo;.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">WHEREAS, the parties have agreed to the Key Terms (see Exhibit A) as
outlined in the Term Sheet, and now formalize their understanding in this Definitive Agreement.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">NOW, THEREFORE, in consideration of the mutual covenants contained
herein, the parties agree as follows:</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">1. Upon signing
this Definitive Agreement, </FONT>ONCOX <FONT STYLE="font-family: Times New Roman, Times, Serif">shall have the exclusive right, until
the expiration of this agreement, to negotiate and execute a definitive licensing agreement for the licensed products with ABVC.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">2. </FONT>ONCOX
<FONT STYLE="font-family: Times New Roman, Times, Serif">has the right to team with partner(s) or transfer the right to a third party
to negotiate and execute a definitive licensing agreement for the licensed products with ABVC.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">3. </FONT>ONCOX
<FONT STYLE="font-family: Times New Roman, Times, Serif">has satisfactorily completed a due diligence investigation of the Licensed Product.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">4. ABVC and
its Representatives shall deal exclusively with </FONT>ONCOX <FONT STYLE="font-family: Times New Roman, Times, Serif">with respect to
any licensing in the same scope or similar arrangement surrounding the Licensed Product.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">IN WITNESS WHEREOF, the parties hereto have executed this Definitive
Agreement as of the Effective Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>[Signature Page]</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ABVC BioPharma, Inc.</FONT></TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">OncoX BioPharma, Inc.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Authorized Signature/Seal</FONT></TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Authorized Signature/Seal</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name&#65306;</FONT></TD>
    <TD STYLE="width: 35%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Uttam Yashwant Patil</I></FONT></TD>
    <TD STYLE="width: 20%">&nbsp;</TD>
    <TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name&#65306;</FONT></TD>
    <TD STYLE="width: 35%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Yen Wen Pin</I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title&#65306;</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CEO</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CEO</FONT></TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 2; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>Exhibit A</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 2pt 5.4pt; width: 27%; border: black 1pt solid; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>LICENSEE</B></FONT></TD>
    <TD STYLE="border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: justify; padding-top: 2pt; padding-bottom: 2pt; padding-left: 5.4pt; width: 73%; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">OncoX BioPharma, Inc. (&ldquo;</FONT>ONCOX<FONT STYLE="font-family: Times New Roman, Times, Serif">&rdquo;)</FONT></TD></TR>
  <TR>
    <TD STYLE="padding: 2pt 5.4pt; vertical-align: top; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>LICENSOR</B></FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: justify; padding-top: 2pt; padding-bottom: 2pt; padding-left: 5.4pt; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">ABVC BioPharma, Inc. (&ldquo;ABVC&rdquo;) and its affiliates</FONT></TD></TR>
  <TR>
    <TD STYLE="padding: 2pt 5.4pt; vertical-align: top; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>THIRD PARTY</B></FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: justify; padding-top: 2pt; padding-bottom: 2pt; padding-left: 5.4pt; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;Third Party&rdquo; means a person or entity other than </FONT>ONCOX <FONT STYLE="font-family: Times New Roman, Times, Serif">or ABVC or their respective affiliates.</FONT></TD></TR>
  <TR>
    <TD STYLE="padding: 2pt 5.4pt; vertical-align: top; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>EFFECTIVE DATE</B></FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: justify; padding-top: 2pt; padding-bottom: 2pt; padding-left: 5.4pt; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">The effective dates of Definitive Agreement related to the Licensed Product that would be the result of Parties&rsquo; discussions</FONT></TD></TR>
  <TR>
    <TD STYLE="padding: 2pt 5.4pt; vertical-align: top; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>LICENSED PRODUCT</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: justify; padding-top: 2pt; padding-bottom: 2pt; padding-left: 5.4pt; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">ABVC&rsquo;s BLEX 404, single-herb botanical drug extract from the dry fruit body of Maitake Mushroom (Grifola Frondosa) for treatment of Myelodysplastic Syndromes (MDS)</FONT></TD></TR>
  <TR>
    <TD STYLE="padding: 2pt 5.4pt; vertical-align: top; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>TERRITORY</B></FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: justify; padding-top: 2pt; padding-bottom: 2pt; padding-left: 5.4pt; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">50% of the Worldwide Markets</FONT></TD></TR>
  <TR>
    <TD STYLE="padding: 2pt 5.4pt; vertical-align: top; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>GOVERNING LAW</B></FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: justify; padding-top: 2pt; padding-bottom: 2pt; padding-left: 5.4pt; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Laws of the United States </FONT></TD></TR>
  <TR>
    <TD STYLE="padding: 2pt 5.4pt; vertical-align: top; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>FIELD OF USE </B></FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: justify; padding-top: 2pt; padding-bottom: 2pt; padding-left: 5.4pt; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Myelodysplastic Syndromes (MDS)</FONT></TD></TR>
  <TR>
    <TD STYLE="padding: 2pt 5.4pt; vertical-align: top; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>RIGHTS GRANTED</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: justify; padding-top: 2pt; padding-bottom: 2pt; padding-left: 5.4pt; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">ABVC shall grant to </FONT>ONCOX <FONT STYLE="font-family: Times New Roman, Times, Serif">an exclusive right within the Territory license to develop and commercialize the Licensed Product in the Territory within the Field of Use.</FONT></TD></TR>
  <TR>
    <TD STYLE="padding: 2pt 5.4pt; vertical-align: top; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>RESPONSIBILITIES &amp; OBLIGATIONS</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: justify; padding-top: 2pt; padding-bottom: 2pt; padding-left: 5.4pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">ABVC
    will be responsible for conducting the clinical development of the Licensed Product outside Territory and communicating the results as
    part of the Product Transfer (PT), which includes delivering the Licensed Product sufficient to support the clinical studies in Territory,
    delivering associated documents, manufacturing protocols, QC protocols, to enable </FONT>ONCOX <FONT STYLE="font-family: Times New Roman, Times, Serif">to
    develop and commercialize the Licensed Product in Territory. </FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">ABVC
    will be responsible to secure the supply of the Licensed Product to</FONT> ONCOX <FONT STYLE="font-family: Times New Roman, Times, Serif">in
    the Territory with an agreed price and quantity while A will secure the purchase of the Licensed Products from ABVC in the Territory with
    committed volume.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">ONCOX <FONT STYLE="font-family: Times New Roman, Times, Serif">shall
    be responsible for completing regulatory filing of IND in the Territory.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">ABVC
    will be responsible for providing the Licensed Product to </FONT>ONCOX <FONT STYLE="font-family: Times New Roman, Times, Serif">at cost,
    to support clinical development in the Field of Use in the Territory. </FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">ONCOX <FONT STYLE="font-family: Times New Roman, Times, Serif">will
    be responsible for further development and commercialization of the Licensed Product in the Field of Use in the Territory, including any
    clinical development, regulatory affairs (including regulatory filings and approvals), and commercialization of the Licensed Product.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">As
    part of this license, </FONT>ONCOX <FONT STYLE="font-family: Times New Roman, Times, Serif">will grant ABVC a perpetual, royalty-free
    right to use and reference any development, regulatory, and market data associated with the Licensed Product in </FONT>ONCOX<FONT STYLE="font-family: Times New Roman, Times, Serif">&rsquo;s
    control.</FONT></P></TD></TR>
  <TR>
    <TD STYLE="padding: 2pt 5.4pt; vertical-align: top; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>EXCLUSIVITY/ </B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>NON-COMPETE</B></P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: justify; padding-top: 2pt; padding-bottom: 2pt; padding-left: 5.4pt; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">During the collaboration, neither Parties nor its affiliates will work on the development of or commercialize in the Territory any products containing Maitake Mushroom as the sole active ingredient or in combination with one or more other active ingredients other than with respect to any other product or usage for which the same parties have previously agreed or will agree to work on together or without a specific mutually agreed to written plan for depression indication. </FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="border-top: Black 1pt solid; padding: 2pt 5.4pt; vertical-align: top; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: black 1pt solid; font-size: 10pt; width: 27%"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>TECHNOLOGY SHARING</B></FONT></TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; padding-top: 2pt; padding-bottom: 2pt; padding-left: 5.4pt; text-align: justify; font-size: 10pt; width: 73%"><FONT STYLE="font-family: Times New Roman, Times, Serif">After the Effective Date, and at a time to be agreed upon by </FONT>ONCOX <FONT STYLE="font-family: Times New Roman, Times, Serif">and ABVC in the Definitive Agreement, ABVC would transfer to </FONT>ONCOX <FONT STYLE="font-family: Times New Roman, Times, Serif">in English that data related to any Licensed Products in ABVC&rsquo;s possession and control that is required by regulatory authorities for opening an IND, NDA.</FONT></TD></TR>
  <TR>
    <TD STYLE="padding: 2pt 5.4pt; vertical-align: top; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>INTELLECTUAL PROPERTY RIGHTS</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: justify; padding-top: 2pt; padding-bottom: 2pt; padding-left: 5.4pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Intellectual
    Property means any patent, copyright, trade secret, trademark or other proprietary right</FONT>&#65307;<FONT STYLE="font-family: Times New Roman, Times, Serif">including
    all their applications , registrations, renewals and extensions. </FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Each Party or its Affiliates owns all rights, title and interest of
    the Intellectual Property developed or controlled by itself and will be responsible for filing and maintaining the Intellectual Property
    in the Territory at its own cost.</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Each Party warrants it does not and will not infringe, violate or misappropriate
    any trademark, patent, copyright, industrial design, trade secret or any other intellectual property or proprietary right of any Third
    Party.</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">No right, title or interest is granted to the other Party in the Definitive
    Agreement, whether expressly or by implication, to any technology or Intellectual Property rights owned by a Party other than pursuant
    to the terms of the Definitive Agreement.</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Each Party will retain an unconditional and
unlimited right of access, inclusion, citation, electronic or photo copy, and regulatory cross reference, without limitation, to any
and all regulatory, technical, and scientific documentations, and any and all communications with any and all regulatory authorities
in the other Party&rsquo;s Territory for all matters related to each Licensed Product during the License Term.</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 2pt 5.4pt; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>MILESTONE &amp; ROYALTY PAYMENTS </B></FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: justify; padding-top: 2pt; padding-bottom: 2pt; padding-left: 5.4pt; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">See Exhibit B.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 2pt 5.4pt; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>TAX</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: justify; padding-top: 2pt; padding-bottom: 2pt; padding-left: 5.4pt; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Payments to Licensor as detailed in Exhibit B are likely considered Licensor&rsquo;s income generated in Territory. Licensor is responsible for income tax, value-added tax, and other related fees levied by Territory government authorities on these payments. If and to the extent that provision is made in law or regulation of Territory for withholding of taxes with respect to any such payment, Licensee shall pay such taxes on behalf of Licensor and provide Licensor with original receipt of such tax payments or withholding.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 2pt 5.4pt; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>NET SALES </B></FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: justify; padding-top: 2pt; padding-bottom: 2pt; padding-left: 5.4pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;Net Sales&rdquo; means the total amount of
    invoices issued by the Licensee for selling the Product of each pack size in the Territory to the Third Parties responsible for distribution
    / logistics, minus the amount of allowable deduction items related to the Product actually provided to non-affiliates as follows:</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">a) sales
    value added tax</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">b) allowance,
    discount or rebate for rejection, defect, recall, return, retroactive price reduction</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Net Sales shall be accounted in accordance with
    arm-length principles, industry standards and practices of the Territory, covering all sales of the Product to the Field of Use in the
    Territory. Any allowance, discount or rebate for any Third Party sales and marketing activities shall not be deducted from the Net Sales
    calculation.</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Licensee shall allow Licensor to appoint
a Third Party independent auditor to audit the financial accounts of Licensee or its affiliates to confirm the reasonableness and accuracy
of the Net Sales calculation of the Product each year during the License Term.</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 2pt 5.4pt; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>LICENSE TERMS</B></FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-top: 2pt; padding-bottom: 2pt; padding-left: 5.4pt; font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The term of licensing for the Licensed Product in the Territory is 20 years.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 2pt 5.4pt; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>MANUFACTURING</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: justify; padding-top: 2pt; padding-bottom: 2pt; padding-left: 5.4pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Both Parties desire Licensee is responsible for
    the Licensed Product API manufacturing under CMO model as global primary supplier. Both Parties agree further study and analysis are to
    be performed for the feasibility from technical and financial perspective before the execution of related manufacturing agreement.</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Manufacturing of Licensed Product finished product
    is subject to negotiation by both Parties.</P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>Exhibit B</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">All payments below are pre-tax total payments in
USD.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="border-top: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-top: 2pt; width: 33%; font-size: 10pt; text-align: center; padding-bottom: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Milestones</B></FONT></TD>
    <TD STYLE="border-top: black 1pt solid; border-bottom: black 1pt solid; padding-top: 2pt; width: 34%; font-size: 10pt; text-align: center; padding-bottom: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Timeline</FONT></TD>
    <TD STYLE="border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; padding-top: 2pt; width: 33%; font-size: 10pt; text-align: center; padding-bottom: 2pt">Payment to ABVC</TD></TR>
  <TR>
    <TD STYLE="border-bottom: black 1pt solid; border-left: black 1pt solid; padding-top: 2pt; font-size: 10pt; text-align: center; padding-bottom: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Upfront</B></FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; padding-top: 2pt; font-size: 10pt; text-align: center; padding-bottom: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Due 30 days after the signature of the Investment Agreement</FONT></TD>
    <TD STYLE="text-align: center; border-right: black 1pt solid; border-bottom: black 1pt solid; padding-top: 2pt; padding-bottom: 2pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>$6,250,000</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(or 1,250,000 shares of ONCOX at $5/share)</P></TD></TR>
  <TR>
    <TD COLSPAN="3" STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-top: 2pt; font-size: 10pt; text-align: center; padding-bottom: 2pt"><B>A cash payment of $100,000 and above at any time will then be deducted from the second milestone payment. </B></TD></TR>
  <TR>
    <TD STYLE="text-align: center; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-top: 2pt; padding-bottom: 2pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Completion</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Of</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Fundraising</B></P></TD>
    <TD STYLE="border-bottom: black 1pt solid; padding-top: 2pt; font-size: 10pt; text-align: center; padding-bottom: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Due 30 days upon completion of next round fundraising</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-top: 2pt; font-size: 10pt; text-align: center; padding-bottom: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>US $625,000</B></FONT></TD></TR>
  <TR>
    <TD STYLE="border-bottom: black 1pt solid; border-left: black 1pt solid; padding-top: 2pt; font-size: 10pt; text-align: center; padding-bottom: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Total Licensing Fee</B></FONT></TD>
    <TD COLSPAN="2" STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-top: 2pt; font-size: 10pt; text-align: center; padding-bottom: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>$6,875,000</B></FONT></TD></TR>
  <TR>
    <TD STYLE="border-bottom: black 1pt solid; border-left: Black 1pt solid; padding-top: 2pt; font-size: 10pt; text-align: center; padding-bottom: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Royalties</B></FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-right: Black 1pt solid; border-bottom: black 1pt solid; padding-top: 2pt; padding-bottom: 2pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">5% of annual Net Sales, accumulated to a total
    of US$6,250,000</P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Royalties shall be payable quarterly on annual
Net Sales of the Licensed Product from the first commercial sale of a Licensed Product in the Territory to the end of License Terms.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 5; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>3
<FILENAME>ea020679001ex10-2_abvcbio.htm
<DESCRIPTION>DEFINITIVE LICENSE AGREEMENT BETWEEN BIOLITE, INC. AND ONCOX BIOPHARMA, INC. DATED MAY 23, 2024
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 10.2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Definitive Licensing Agreement</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This Definitive Licensing Agreement (&ldquo;Agreement&rdquo;) is entered
into this May 23, 2024 (the &ldquo;Effective Date&rdquo;) by and between:</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: justify; width: 0in"></TD><TD STYLE="width: 0.25in; text-align: justify">(1)</TD><TD STYLE="text-align: justify">BIOLITE, INC., a company registered in Taiwan. (&ldquo;BIOLITE&rdquo;);
and</TD>
</TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: justify; width: 0in"></TD><TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">(2)</FONT></TD><TD STYLE="text-align: justify">OncoX BioPharma, Inc. (&ldquo;ONCOX&rdquo;), a company registered
in the British Virgin Islands.; and</TD>
</TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">BIOLITE and ONCOX shall be referred to individually as a &ldquo;Party&rdquo;
and collectively as the &ldquo;Parties&rdquo;.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">WHEREAS, the parties have agreed to the Key Terms (see Exhibit A) as
outlined in the Term Sheet, and now formalize their understanding in this Definitive Agreement.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">NOW, THEREFORE, in consideration of the mutual covenants contained
herein, the parties agree as follows:</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">1. Upon signing
this Definitive Agreement, </FONT>ONCOX <FONT STYLE="font-family: Times New Roman, Times, Serif">shall have the exclusive right, until
the expiration of this agreement, to negotiate and execute a definitive licensing agreement for the licensed products with BIOLITE.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">2. </FONT>ONCOX
<FONT STYLE="font-family: Times New Roman, Times, Serif">has the right to team with partner(s) or transfer the right to a third party
to negotiate and execute a definitive licensing agreement for the licensed products with BIOLITE.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">3. </FONT>ONCOX
<FONT STYLE="font-family: Times New Roman, Times, Serif">has satisfactorily completed a due diligence investigation of the Licensed Product.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">4. BIOLITE
and its Representatives shall deal exclusively with </FONT>ONCOX <FONT STYLE="font-family: Times New Roman, Times, Serif">with respect
to any licensing in the same scope or similar arrangement surrounding the Licensed Product.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">IN WITNESS WHEREOF, the parties hereto have executed this Definitive
Agreement as of the Effective Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>[Signature Page]</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">BIOLITE, INC.</P></TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">OncoX BioPharma, Inc.</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Authorized Signature/Seal</FONT></TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Authorized Signature/Seal</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name&#65306;</FONT></TD>
    <TD STYLE="width: 35%"><I>Tsung Shann Jiang</I></TD>
    <TD STYLE="width: 20%">&nbsp;</TD>
    <TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name&#65306;</FONT></TD>
    <TD STYLE="width: 35%"><I>Yen Wen Pin</I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title&#65306;</FONT></TD>
    <TD></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CEO</FONT></TD>
    <TD></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CEO</FONT></TD>
    <TD></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>Exhibit A</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 2pt 5.4pt; width: 27%; border: black 1pt solid; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>LICENSEE</B></FONT></TD>
    <TD STYLE="text-align: justify; border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; padding-top: 2pt; padding-bottom: 2pt; padding-left: 5.4pt; width: 73%; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">OncoX BioPharma, Inc. (&ldquo;</FONT>ONCOX<FONT STYLE="font-family: Times New Roman, Times, Serif">&rdquo;)</FONT></TD></TR>
  <TR>
    <TD STYLE="padding: 2pt 5.4pt; vertical-align: top; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>LICENSOR</B></FONT></TD>
    <TD STYLE="text-align: justify; border-right: black 1pt solid; border-bottom: black 1pt solid; padding-top: 2pt; padding-bottom: 2pt; padding-left: 5.4pt; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">BIOLITE, INC. (&ldquo;BIOLITE&rdquo;) and its affiliates</FONT></TD></TR>
  <TR>
    <TD STYLE="padding: 2pt 5.4pt; vertical-align: top; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>THIRD PARTY</B></FONT></TD>
    <TD STYLE="text-align: justify; border-right: black 1pt solid; border-bottom: black 1pt solid; padding-top: 2pt; padding-bottom: 2pt; padding-left: 5.4pt; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;Third Party&rdquo; means a person or entity other than </FONT>ONCOX <FONT STYLE="font-family: Times New Roman, Times, Serif">or BIOLITE or their respective affiliates.</FONT></TD></TR>
  <TR>
    <TD STYLE="padding: 2pt 5.4pt; vertical-align: top; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>EFFECTIVE DATE</B></FONT></TD>
    <TD STYLE="text-align: justify; border-right: black 1pt solid; border-bottom: black 1pt solid; padding-top: 2pt; padding-bottom: 2pt; padding-left: 5.4pt; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">The effective dates of Definitive Agreement related to the Licensed Product that would be the result of Parties&rsquo; discussions</FONT></TD></TR>
  <TR>
    <TD STYLE="padding: 2pt 5.4pt; vertical-align: top; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>LICENSED PRODUCT</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P></TD>
    <TD STYLE="text-align: justify; border-right: black 1pt solid; border-bottom: black 1pt solid; padding-top: 2pt; padding-bottom: 2pt; padding-left: 5.4pt; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">BIOLITE&rsquo;s BLEX 404, single-herb botanical drug extract from the dry fruit body of Maitake Mushroom (Grifola Frondosa) for treatment of Myelodysplastic Syndromes (MDS)</FONT></TD></TR>
  <TR>
    <TD STYLE="padding: 2pt 5.4pt; vertical-align: top; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>TERRITORY</B></FONT></TD>
    <TD STYLE="text-align: justify; border-right: black 1pt solid; border-bottom: black 1pt solid; padding-top: 2pt; padding-bottom: 2pt; padding-left: 5.4pt; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">50% of the Worldwide Markets</FONT></TD></TR>
  <TR>
    <TD STYLE="padding: 2pt 5.4pt; vertical-align: top; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>GOVERNING LAW</B></FONT></TD>
    <TD STYLE="text-align: justify; border-right: black 1pt solid; border-bottom: black 1pt solid; padding-top: 2pt; padding-bottom: 2pt; padding-left: 5.4pt; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Laws of the United States </FONT></TD></TR>
  <TR>
    <TD STYLE="padding: 2pt 5.4pt; vertical-align: top; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>FIELD OF USE </B></FONT></TD>
    <TD STYLE="text-align: justify; border-right: black 1pt solid; border-bottom: black 1pt solid; padding-top: 2pt; padding-bottom: 2pt; padding-left: 5.4pt; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Myelodysplastic Syndromes (MDS)</FONT></TD></TR>
  <TR>
    <TD STYLE="padding: 2pt 5.4pt; vertical-align: top; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>RIGHTS GRANTED</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P></TD>
    <TD STYLE="text-align: justify; border-right: black 1pt solid; border-bottom: black 1pt solid; padding-top: 2pt; padding-bottom: 2pt; padding-left: 5.4pt; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">BIOLITE shall grant to </FONT>ONCOX <FONT STYLE="font-family: Times New Roman, Times, Serif">an exclusive right within the Territory license to develop and commercialize the Licensed Product in the Territory within the Field of Use.</FONT></TD></TR>
  <TR>
    <TD STYLE="padding: 2pt 5.4pt; vertical-align: top; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>RESPONSIBILITIES &amp; OBLIGATIONS</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P></TD>
    <TD STYLE="text-align: justify; border-right: black 1pt solid; border-bottom: black 1pt solid; padding-top: 2pt; padding-bottom: 2pt; padding-left: 5.4pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">BIOLITE
    will be responsible for conducting the clinical development of the Licensed Product outside Territory and communicating the results as
    part of the Product Transfer (PT), which includes delivering the Licensed Product sufficient to support the clinical studies in Territory,
    delivering associated documents, manufacturing protocols, QC protocols, to enable </FONT>ONCOX <FONT STYLE="font-family: Times New Roman, Times, Serif">to
    develop and commercialize the Licensed Product in Territory. </FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">BIOLITE
    will be responsible to secure the supply of the Licensed Product to</FONT> ONCOX <FONT STYLE="font-family: Times New Roman, Times, Serif">in
    the Territory with an agreed price and quantity while A will secure the purchase of the Licensed Products from BIOLITE in the Territory
    with committed volume.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">ONCOX <FONT STYLE="font-family: Times New Roman, Times, Serif">shall
    be responsible for completing regulatory filing of IND in the Territory.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">BIOLITE
    will be responsible for providing the Licensed Product to </FONT>ONCOX <FONT STYLE="font-family: Times New Roman, Times, Serif">at cost,
    to support clinical development in the Field of Use in the Territory. </FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">ONCOX <FONT STYLE="font-family: Times New Roman, Times, Serif">will
    be responsible for further development and commercialization of the Licensed Product in the Field of Use in the Territory, including any
    clinical development, regulatory affairs (including regulatory filings and approvals), and commercialization of the Licensed Product.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">As
    part of this license, </FONT>ONCOX <FONT STYLE="font-family: Times New Roman, Times, Serif">will grant BIOLITE a perpetual, royalty-free
    right to use and reference any development, regulatory, and market data associated with the Licensed Product in </FONT>ONCOX<FONT STYLE="font-family: Times New Roman, Times, Serif">&rsquo;s
    control.</FONT></P></TD></TR>
  <TR>
    <TD STYLE="padding: 2pt 5.4pt; vertical-align: top; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>EXCLUSIVITY/ </B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>NON-COMPETE</B></P></TD>
    <TD STYLE="text-align: justify; border-right: black 1pt solid; border-bottom: black 1pt solid; padding-top: 2pt; padding-bottom: 2pt; padding-left: 5.4pt; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">During the collaboration, neither Parties nor its affiliates will work on the development of or commercialize in the Territory any products containing Maitake Mushroom as the sole active ingredient or in combination with one or more other active ingredients other than with respect to any other product or usage for which the same parties have previously agreed or will agree to work on together or without a specific mutually agreed to written plan for depression indication. </FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="padding: 2pt 5.4pt; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; vertical-align: top; border-left: black 1pt solid; font-size: 10pt; width: 27%"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>TECHNOLOGY SHARING</B></FONT></TD>
    <TD STYLE="text-align: justify; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 2pt; padding-bottom: 2pt; padding-left: 5.4pt; font-size: 10pt; width: 73%"><FONT STYLE="font-family: Times New Roman, Times, Serif">After the Effective Date, and at a time to be agreed upon by </FONT>ONCOX <FONT STYLE="font-family: Times New Roman, Times, Serif">and BIOLITE in the Definitive Agreement, BIOLITE would transfer to </FONT>ONCOX <FONT STYLE="font-family: Times New Roman, Times, Serif">in English that data related to any Licensed Products in BIOLITE&rsquo;s possession and control that is required by regulatory authorities for opening an IND, NDA.</FONT></TD></TR>
  <TR>
    <TD STYLE="padding: 2pt 5.4pt; vertical-align: top; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: black 1pt solid">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>INTELLECTUAL PROPERTY RIGHTS</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P></TD>
    <TD STYLE="text-align: justify; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 2pt; padding-bottom: 2pt; padding-left: 5.4pt">
    <P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Intellectual
    Property means any patent, copyright, trade secret, trademark or other proprietary right</FONT>&#65307;<FONT STYLE="font-family: Times New Roman, Times, Serif">including
    all their applications , registrations, renewals and extensions. </FONT></P>
    <P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Each Party or its Affiliates owns all rights, title and interest of
    the Intellectual Property developed or controlled by itself and will be responsible for filing and maintaining the Intellectual Property
    in the Territory at its own cost.</P>
    <P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Each Party warrants it does not and will not infringe, violate or misappropriate
    any trademark, patent, copyright, industrial design, trade secret or any other intellectual property or proprietary right of any Third
    Party.</P>
    <P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">No right, title or interest is granted to the other Party in the Definitive
    Agreement, whether expressly or by implication, to any technology or Intellectual Property rights owned by a Party other than pursuant
    to the terms of the Definitive Agreement.</P>
    <P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Each Party will retain an unconditional and unlimited right of
access, inclusion, citation, electronic or photo copy, and regulatory cross reference, without limitation, to any and all regulatory,
technical, and scientific documentations, and any and all communications with any and all regulatory authorities in the other Party&rsquo;s
Territory for all matters related to each Licensed Product during the License Term.</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 2pt 5.4pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: black 1pt solid; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>MILESTONE &amp; ROYALTY PAYMENTS </B></FONT></TD>
    <TD STYLE="text-align: justify; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 2pt; padding-bottom: 2pt; padding-left: 5.4pt; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">See Exhibit B.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 2pt 5.4pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: black 1pt solid">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>TAX</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P></TD>
    <TD STYLE="text-align: justify; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 2pt; padding-bottom: 2pt; padding-left: 5.4pt; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Payments to Licensor as detailed in Exhibit B are likely considered Licensor&rsquo;s income generated in Territory. Licensor is responsible for income tax, value-added tax, and other related fees levied by Territory government authorities on these payments. If and to the extent that provision is made in law or regulation of Territory for withholding of taxes with respect to any such payment, Licensee shall pay such taxes on behalf of Licensor and provide Licensor with original receipt of such tax payments or withholding.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 2pt 5.4pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: black 1pt solid; font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>NET SALES </B></FONT></TD>
    <TD STYLE="text-align: justify; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 2pt; padding-bottom: 2pt; padding-left: 5.4pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;Net Sales&rdquo; means the total amount of
    invoices issued by the Licensee for selling the Product of each pack size in the Territory to the Third Parties responsible for distribution
    / logistics, minus the amount of allowable deduction items related to the Product actually provided to non-affiliates as follows:</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">a) sales
    value added tax</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">b) allowance,
    discount or rebate for rejection, defect, recall, return, retroactive price reduction</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Net Sales shall be accounted in accordance with
    arm-length principles, industry standards and practices of the Territory, covering all sales of the Product to the Field of Use in the
    Territory. Any allowance, discount or rebate for any Third Party sales and marketing activities shall not be deducted from the Net Sales
    calculation.</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Licensee shall allow Licensor to appoint
a Third Party independent auditor to audit the financial accounts of Licensee or its affiliates to confirm the reasonableness and accuracy
of the Net Sales calculation of the Product each year during the License Term.</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 2pt 5.4pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: black 1pt solid; font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>LICENSE TERMS</B></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 2pt; padding-bottom: 2pt; padding-left: 5.4pt; font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The term of licensing for the Licensed Product in the Territory is 20 years.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 2pt 5.4pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: black 1pt solid">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>MANUFACTURING</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P></TD>
    <TD STYLE="text-align: justify; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 2pt; padding-bottom: 2pt; padding-left: 5.4pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Both Parties desire Licensee is responsible for
    the Licensed Product API manufacturing under CMO model as global primary supplier. Both Parties agree further study and analysis are to
    be performed for the feasibility from technical and financial perspective before the execution of related manufacturing agreement.</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Manufacturing of Licensed Product finished product
    is subject to negotiation by both Parties.</P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>Exhibit B</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">All payments below are pre-tax total payments in
USD.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="padding: 2pt 5.4pt; border-top: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; width: 33%; font-size: 10pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Milestones</B></FONT></TD>
    <TD STYLE="padding: 2pt 5.4pt; border-top: black 1pt solid; border-bottom: black 1pt solid; width: 34%; font-size: 10pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Timeline</FONT></TD>
    <TD STYLE="padding: 2pt 5.4pt; text-align: center; width: 33%; border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; font-size: 10pt">Payment to BIOLITE</TD></TR>
  <TR>
    <TD STYLE="padding: 2pt 5.4pt; border-bottom: black 1pt solid; border-left: black 1pt solid; font-size: 10pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Upfront</B></FONT></TD>
    <TD STYLE="padding: 2pt 5.4pt; border-bottom: black 1pt solid; font-size: 10pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Due 30 days after the signature of the Investment Agreement</FONT></TD>
    <TD STYLE="padding: 2pt 5.4pt; text-align: center; border-right: black 1pt solid; border-bottom: black 1pt solid">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>$6,250,000</B></P>
    <P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">(or 1,250,000 shares of ONCOX at $5/share)</P></TD></TR>
  <TR>
    <TD COLSPAN="3" STYLE="padding: 2pt 5.4pt; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; font-size: 10pt; text-align: center"><B>A cash payment of $100,000 and above at any time will then be deducted from the second milestone payment. </B></TD></TR>
  <TR>
    <TD STYLE="padding: 2pt 5.4pt; text-align: center; border-bottom: black 1pt solid; border-left: black 1pt solid">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Completion </B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Of</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Fundraising</B></P></TD>
    <TD STYLE="padding: 2pt 5.4pt; border-bottom: black 1pt solid; font-size: 10pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Due 30 days upon completion of next round fundraising</FONT></TD>
    <TD STYLE="padding: 2pt 5.4pt; border-right: black 1pt solid; border-bottom: black 1pt solid; font-size: 10pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>US $625,000</B></FONT></TD></TR>
  <TR>
    <TD STYLE="padding: 2pt 5.4pt; border-bottom: black 1pt solid; border-left: black 1pt solid; font-size: 10pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Total Licensing Fee</B></FONT></TD>
    <TD COLSPAN="2" STYLE="padding: 2pt 5.4pt; border-right: black 1pt solid; border-bottom: black 1pt solid; font-size: 10pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>$6,875,000</B></FONT></TD></TR>
  <TR>
    <TD STYLE="padding: 2pt 5.4pt; border-bottom: black 1pt solid; border-left: Black 1pt solid; font-size: 10pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Royalties</B></FONT></TD>
    <TD COLSPAN="2" STYLE="padding: 2pt 5.4pt; text-align: center; vertical-align: top; border-right: Black 1pt solid; border-bottom: black 1pt solid">
    <P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>
    <P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">5% of annual Net Sales, accumulated to a total of US$6,250,000</P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Royalties shall be payable quarterly on annual
Net Sales of the Licensed Product from the first commercial sale of a Licensed Product in the Territory to the end of License Terms.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 5; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>4
<FILENAME>ea020679001ex99-1_abvcbio.htm
<DESCRIPTION>PRESS RELEASE
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Exhibit 99.1</P>

<P STYLE="text-align: center; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><IMG SRC="ex99-1_001.jpg" ALT=""></P>

<P STYLE="text-align: center; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">Immunity Boosting Combination Therapy for Myelodysplastic Syndrome Treatment: A Milestone Collaboration Between ABVC and OncoX, ABVC Eligible
to Receive Aggregate Income of $13.75M and Royalties of up to $12.50M</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Fremont, CA (May 24, 2024)</B> &ndash; ABVC
BioPharma, Inc. (NASDAQ: ABVC) (&ldquo;Company&rdquo;), a clinical-stage biopharmaceutical company developing therapeutic solutions in ophthalmology,
CNS (central nervous systems), and Oncology/Hematology, announced today a significant step in the fight against Myelodysplastic Syndrome.
The Company and its subsidiary BioLite, Inc. have entered into a definitive agreement with OncoX BioPharma, Inc., a private company registered
in the British Virgin Islands, to collaborate on a combination therapy. We believe this therapy holds the potential to revolutionize Myelodysplastic
Syndrome treatment and significantly improve patient outcomes. ABVC and its subsidiary are eligible to receive an aggregate license fee
of $12,500,000 in the form of cash or shares of OncoX securities within 30 days of executing the agreement, with an additional aggregate
milestone payment of $1,250,000 in cash after OncoX&rsquo;s next round of fundraising, of which there can be no guarantee. OncoX may remit partial
cash payments of at least $100,000 to the licensing fees, which would be deductible from the second milestone payment. ABVC and its subsidiary
are also entitled to receive royalties of 5% of net sales, up to $12,500,000, after the launch of the licensed product, which remains
uncertain. There is no guarantee that ABVC or its subsidiary will receive any of the fees listed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The United States Food &amp; Drug Administration
(US FDA) has granted its approval to four INDs, a testament to the safety and efficacy of our investigational new drugs. These include
ABV-1501 (IND 129575) for Triple Negative Breast Cancer (TNBC), ABV-1519 (IND 161602) for Non-Small Cell Lung Cancer (NSCLC), ABV-1702
(IND 131300) for Myelodysplastic Syndrome (MDS), and ABV-1703 (IND 136309) for Pancreatic Cancer Therapy. The Investigational New Drug
(IND) application for ABV-1703 proposed the clinical investigation of BLEX 404 as a Combination Therapy Drug with Chemotherapy. The active
ingredient of BLEX 404 is the <I>&beta;</I>-glucan extracted from <I>Grifola frondosa</I> (maitake mushrooms), an edible fungus with
high medical and commercial values in Asia; it contains various bioactive constituents such as polysaccharides, pyrrole alkaloids, ergosterol,
etc., and has been widely served as functional foods for a long time in daily life.<SUP>1</SUP></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">Myelodysplastic
Syndromes, a group of diverse bone marrow disorders characterized by ineffective blood cell production, have posed substantial challenges
to conventional treatment methodologies.<SUP>2</SUP> MDS and its treatments can significantly impact patients&rsquo; quality of life due to
symptoms such as fatigue, anemia, and infection risk. More effective supportive care strategies and symptom management approaches are
needed to enhance patients&rsquo; well-being and functional status.<SUP>3</SUP></FONT> In vitro results have proven that <I>&beta;</I>-glucan
of MD-fraction, a <FONT STYLE="font-size: 10pt">key ingredient of BLEX 404, enhances bone marrow colony formation and reduces chemotherapy
toxicity.<SUP>4</SUP></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>1</SUP></FONT></TD><TD STYLE="text-align: justify">https://www.sciencedirect.com/science/article/abs/pii/S0960852407001083?via%3Dihub</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>2</SUP></FONT></TD><TD STYLE="text-align: justify">https://my.clevelandclinic.org/health/diseases/6192-myelodysplastic-syndrome-myelodysplasia</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>3</SUP></FONT></TD><TD STYLE="text-align: justify">https://pubmed.ncbi.nlm.nih.gov/34045662/</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><SUP>4</SUP></TD><TD STYLE="text-align: justify">https://www.sciencedirect.com/science/article/abs/pii/S1567576903002765#:~:text=Maitake%20beta%2Dglucan%20MD%2Dfraction,doxorubicin%20toxicity%20in%20vitro%20%2D%20ScienceDirect</TD>
</TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;This landmark collaboration aims to revolutionize
MDS treatment by developing a novel combination therapy. We expect this innovative combination therapy, the result of extensive research
and development efforts, to significantly improve patient outcomes by addressing the underlying mechanisms of MDS more comprehensively
than current treatments allow. By leveraging synergistic effects between multiple therapeutic agents, this approach aims to enhance efficacy
while minimizing adverse effects, offering new hope to patients and healthcare professionals alike, said Dr. Uttam Patil, ABVC&rsquo;s Chief
Executive Officer. He added, &ldquo;Through this collaboration, we aim to redefine the standard of care for MDS patients, empowering them
with more effective and personalized treatment options.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;We are thrilled to announce this definitive
agreement with ABVC, which marks a pivotal moment in our ongoing commitment to advancing the field of oncology and hematological disorders,&rdquo;
said Wen-Pin Yen, CEO of OncoX. He added, &ldquo;OncoX shares this enthusiasm for the collaboration&rsquo;s potential impact and is excited
to combine the scientific expertise of ABVC&rsquo;s innovative approach to develop a therapy that can potentially transform the lives of MDS
patients. This partnership represents a significant step forward in our shared mission to address unmet medical needs and improve patient
outcomes.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Under the terms of the agreement, ABVC grants
OncoX exclusive rights for one of ABVC&rsquo;s four products in its Oncology pipeline to develop, manufacture, and commercialize BLEX 404, a
promising therapeutic agent for the treatment of Myelodysplastic Syndromes. The license has a term of 20 years within a specified territory.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Management
believes the Company&rsquo;s product pipeline has excellent market potential. The global cancer therapeutics market is expected to be worth
around US$393.61 billion by 2032, up from US$164 billion in 2022, growing at a CAGR of 9.20% from 2023 to 2032.<FONT STYLE="font-family: Times New Roman, Times, Serif"><SUP>5</SUP></FONT>
Myelodysplastic Syndrome (MDS) Treatment market is projected to reach US$ 6102.7 million in 2029, increasing from US$ 3270 million in
2022, with the CAGR of 9.2% during the period of 2023 to 2029.<FONT STYLE="font-family: Times New Roman, Times, Serif"><SUP>6</SUP></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For more information about ABVC and its subsidiaries,
stay updated on the latest updates or visit https://abvcpharma.com. <B>ABVC urges its shareholders to sign up on the Company&rsquo;s website
for the latest news alerts; visit </B>https://abvcpharma.com/?page_id=17707</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>About ABVC BioPharma &amp; Its Industry</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">ABVC BioPharma is a clinical-stage biopharmaceutical
company with an active pipeline of six drugs and one medical device (ABV-1701/Vitargus<SUP>&reg;</SUP>) under development. For its drug
products, the Company utilizes in-licensed technology from its network of world-renowned research institutions to conduct proof-of-concept
trials through Phase II of clinical development. The Company&rsquo;s network of research institutions includes Stanford University, the University
of California at San Francisco, and Cedars-Sinai Medical Center. For Vitargus<SUP>&reg;</SUP>, the Company intends to conduct global clinical
trials through Phase III.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>5</SUP></FONT></TD><TD STYLE="text-align: justify">https://www.precedenceresearch.com/cancer-therapeutics-market</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>6</SUP></FONT></TD><TD STYLE="text-align: justify">https://www.linkedin.com/pulse/myelodysplastic-syndrome-mds-treatment-market-insights-qw6uc/</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Forward-Looking Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This press release contains &ldquo;forward-looking
statements.&rdquo; Such statements may be preceded by the words &ldquo;intends,&rdquo; &ldquo;may,&rdquo; &ldquo;will,&rdquo; &ldquo;plans,&rdquo;
&ldquo;expects,&rdquo; &ldquo;anticipates,&rdquo; &ldquo;projects,&rdquo; &ldquo;predicts,&rdquo; &ldquo;estimates,&rdquo; &ldquo;aims,&rdquo; &ldquo;believes,&rdquo;
&ldquo;hopes,&rdquo; &ldquo;potential,&rdquo; or similar words. Forward-looking statements are not guarantees of future performance, are based
on certain assumptions, and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company&rsquo;s control,
and cannot be predicted or quantified, and, consequently, actual results may differ materially from those expressed or implied by such
forward-looking statements. None of the outcomes expressed herein are guaranteed. Such risks and uncertainties include, without limitation,
risks and uncertainties associated with (i) our inability to manufacture our product candidates on a commercial scale on our own, or in
collaboration with third parties; (ii) difficulties in obtaining financing on commercially reasonable terms; (iii) changes in the size
and nature of our competition; (iv) loss of one or more key executives or scientists; and (v) difficulties in securing regulatory approval
to proceed to the next level of the clinical trials or to market our product candidates. More detailed information about the Company and
the risk factors that may affect the realization of forward-looking statements is set forth in the Company&rsquo;s filings with the Securities
and Exchange Commission (SEC), including the Company&rsquo;s Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors are
urged to read these documents free of charge on the SEC&rsquo;s website at&nbsp;http://www.sec.gov. The Company assumes no obligation to publicly
update or revise its forward-looking statements as a result of new information, future events or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This press release does not constitute an offer
to sell, or the solicitation of an offer to buy any of the Company&rsquo;s securities, nor shall such securities be offered or sold in the United
States absent registration or an applicable exemption from registration, nor shall there be any offer, solicitation or sale of any of
the Company&rsquo;s securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration
or qualification under the securities laws of such state or jurisdiction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Contact:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Leeds Chow</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Email: leedschow@ambrivis.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>ex99-1_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex99-1_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !# ' # 2(  A$! Q$!_\0
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MH%B]K%,\JM(9-S@ \@#M]*U:XYJ*DU!W1Z=)S<$ZBL^ISWCII%\$:LT)<2"
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I,%3W!^AR*NT44 %%%% !1110 4444 %%%% !1110 4444 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>6
<FILENAME>abvc-20240524.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.22b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: 86o5s7xRiXhun8uDb31cWa2H6aPty5BxKZkxsmx+HYkqDyQhZd/fhC58kfVW8QAG -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:srt="http://fasb.org/srt/2023" xmlns:srt-types="http://fasb.org/srt-types/2023" xmlns:ABVC="http://abvcpharma.com/20240524" elementFormDefault="qualified" targetNamespace="http://abvcpharma.com/20240524">
    <annotation>
      <appinfo>
        <link:roleType roleURI="http://abvcpharma.com/role/Cover" id="Cover">
          <link:definition>00000001 - Document - Cover</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:linkbaseRef xlink:type="simple" xlink:href="abvc-20240524_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="abvc-20240524_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd" />
    <import namespace="http://fasb.org/us-gaap/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd" />
    <import namespace="http://fasb.org/us-types/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2023" schemaLocation="https://xbrl.sec.gov/country/2023/country-2023.xsd" />
    <import namespace="http://fasb.org/srt/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd" />
    <import namespace="http://fasb.org/srt-types/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>7
<FILENAME>abvc-20240524_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.22b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>8
<FILENAME>abvc-20240524_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.22b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://abvcpharma.com/role/Cover" xlink:href="abvc-20240524.xsd#Cover" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://abvcpharma.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139653448882112">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>May 24, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">May 24,  2024<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-40700<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">ABVC BIOPHARMA, INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001173313<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">26-0014658<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">NV<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">44370 Old Warm Springs Blvd.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Fremont<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">94538<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">510<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">668-0881<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.001 per share<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ABVC<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>11
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MTNUV*494]@:*F_J;$L;P!!(3QUFRMSA=284+U?5U6O8#BMOX3$8B$ 9F-7F
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M-3]<<09SP3X ]Q=2FL.)W;<6_W88_ =02P,$%     @ "$"X6)^@&_"Q @
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M\SR. !9GD*88 J<11S &P %#TG1X#SY['R73>RHY_U=3_ 102P,$%     @
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MH'Q3F:B\]E-L.>F.7F=Z_S!YU!Y:YU;*O8=7LN48<?R>Y0]02P,$%     @
M"$"X6"0>FZ*M    ^ $  !H   !X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L
M<[61/0Z#, R%KQ+E #50J4,%3%U8*RX0!?,C$A+%K@JW+X4!D#IT8;*>+7_O
MR4Z?:!1W;J"V\R1&:P;*9,OL[P"D6[2*+L[C,$]J%ZSB688&O-*]:A"2*+I!
MV#-DGNZ9HIP\_D-T==UI?#C]LCCP#S"\7>BI160I2A4:Y$S":+8VP5+BRTR6
MHJ@R&8HJEG!:(.+)(&UI5GVP3TZTYWD7-_=%KLWC":[?#'!X=/X!4$L#!!0
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M&G_FB^$_7G\!4$L! A0#%     @ "$"X6 =!36*!    L0   !
M     ( !     &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4    "  (0+A8'.?7
MMNX    K @  $0              @ &O    9&]C4')O<',O8V]R92YX;6Q0
M2P$"% ,4    "  (0+A8F5R<(Q &  "<)P  $P              @ ', 0
M>&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0    (  A N%BK4%H^3P0  ((0
M   8              " @0T(  !X;"]W;W)K<VAE971S+W-H965T,2YX;6Q0
M2P$"% ,4    "  (0+A8GZ ;\+$"  #B#   #0              @ &2#
M>&PO<W1Y;&5S+GAM;%!+ 0(4 Q0    (  A N%B7BKL<P    !,"   +
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4!08     "0 ) #X"  #F$P     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.1.1.u2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>3</UnitCount>
  <MyReports>
    <Report instance="ea0206790-8k_abvcbio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://abvcpharma.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>abvc-20240524.xsd</File>
    <File>abvc-20240524_lab.xml</File>
    <File>abvc-20240524_pre.xml</File>
    <File doctype="8-K" isOnlyDei="true" isUsgaap="true" original="ea0206790-8k_abvcbio.htm">ea0206790-8k_abvcbio.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="22">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>17
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "ea0206790-8k_abvcbio.htm": {
   "nsprefix": "ABVC",
   "nsuri": "http://abvcpharma.com/20240524",
   "dts": {
    "schema": {
     "local": [
      "abvc-20240524.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "abvc-20240524_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "abvc-20240524_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "ea0206790-8k_abvcbio.htm"
     ]
    }
   },
   "keyStandard": 22,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2023": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 59,
   "unitCount": 3,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2023": 22
   },
   "report": {
    "R1": {
     "role": "http://abvcpharma.com/role/Cover",
     "longName": "00000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "AsOf2024-05-24",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0206790-8k_abvcbio.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-05-24",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0206790-8k_abvcbio.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AnnualInformationForm": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AnnualInformationForm",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Information Form",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_AuditedAnnualFinancialStatements": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditedAnnualFinancialStatements",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Audited Annual Financial Statements",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CountryRegion": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CountryRegion",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Country Region",
        "documentation": "Region code of country"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentAccountingStandard": {
     "xbrltype": "accountingStandardItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentAccountingStandard",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Accounting Standard",
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r13",
      "r14"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodStartDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodStartDate",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period Start Date",
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "dei_DocumentRegistrationStatement": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentRegistrationStatement",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Registration Statement",
        "documentation": "Boolean flag that is true only for a form used as a registration statement."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_DocumentShellCompanyEventDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentShellCompanyEventDate",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Event Date",
        "documentation": "Date of event requiring a shell company report."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentShellCompanyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentShellCompanyReport",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Report",
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine3": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine3",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Three",
        "documentation": "Address Line 3 such as an Office Park"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Bankruptcy Proceedings, Reporting Current",
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not.  Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Elected Not To Use the Extended Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "dei_EntityPrimarySicNumber": {
     "xbrltype": "sicNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityPrimarySicNumber",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Primary SIC Number",
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "dei_Extension": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Extension",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Extension",
        "documentation": "Extension number for local phone number."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_NoTradingSymbolFlag": {
     "xbrltype": "trueItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "NoTradingSymbolFlag",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Trading Symbol Flag",
        "documentation": "Boolean flag that is true only for a security having no trading symbol."
       }
      }
     },
     "auth_ref": []
    },
    "dei_OtherReportingStandardItemNumber": {
     "xbrltype": "otherReportingStandardItemNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "OtherReportingStandardItemNumber",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Reporting Standard Item Number",
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_Security12gTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12gTitle",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(g) Security",
        "documentation": "Title of a 12(g) registered security."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_SecurityReportingObligation": {
     "xbrltype": "securityReportingObligationItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityReportingObligation",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Reporting Obligation",
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "g"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12, 13, 15d"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r8": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r9": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "15",
   "Subsection": "d"
  },
  "r10": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Section": "14a",
   "Number": "240",
   "Subsection": "12"
  },
  "r11": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r12": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r13": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r14": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r15": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r16": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r17": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r18": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r19": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>18
<FILENAME>0001213900-24-046419-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001213900-24-046419-xbrl.zip
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M(D!Q:'Q0WR@$QE 1IHO.D:];N\&]H[;XQOUR[V&U6_X'4$L#!!0    (  A
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M2^>.4\'00>-^;+7W"0,(<=+M+HO.)V/^B16;9N'Z8='Y/0TEMCZUG+9?V&"
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MY156Z#3+BYKA*IF*]M>TL5<\ZQTYRYUXUCMR%OSESWJ_-->1VDUH?>UAH06
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MBJR=R)F60CM9X#[.DOGY*>1[;Q*Z09(&L=1ULCR:I\T@O6DSV$)$J5A/0WL
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MRWNV#Y;DG?>YWA7-DC)OUF$!'I[N6OHGIA(0B/LO HN^MV^R>O6\XX12UW'
MI8IR9T[H7@9-B@5*CDEW9>#ELO:ZUJU6E45[8,PO<G##7NY#X"T*V'S9N?N]
MQ7/W*TND+\8S6T>=^H4^X>.;<]HZ_ ]02P,$%     @ "$"X6/1"-G#,%
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M$O0*-JVB*32Q<;IS=NS0D5"R*RYBA8>OF,@!7T!\F5,N8/04<:+/]"3ZB6@
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MNV[K%4V^_\;L&PBP>3TM"Y9TR7 89UO_; X#B\V=O$OY8.G.!_[*;,JY60\
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M   1              "  0    !A8G9C+3(P,C0P-3(T+GAS9%!+ 0(4 Q0
M   (  A N%@M$PV)_0H  ("&   5              "  5X#  !A8G9C+3(P
M,C0P-3(T7VQA8BYX;6Q02P$"% ,4    "  (0+A8BZ9,<ED'  #95P  %0
M            @ &.#@  86)V8RTR,#(T,#4R-%]P<F4N>&UL4$L! A0#%
M  @ "$"X6,<\P\ED%0  E'8  !@              ( !&A8  &5A,#(P-C<Y
M,"TX:U]A8G9C8FEO+FAT;5!+ 0(4 Q0    (  A N%BO.NJAJQ0  %22   =
M              "  ;0K  !E83 R,#8W.3 P,65X,3 M,5]A8G9C8FEO+FAT
M;5!+ 0(4 Q0    (  A N%CT0C9PS!0  $.1   =              "  9I
M  !E83 R,#8W.3 P,65X,3 M,E]A8G9C8FEO+FAT;5!+ 0(4 Q0    (  A
MN%@"YP@!"10  $-)   =              "  :%5  !E83 R,#8W.3 P,65X
F.3DM,5]A8G9C8FEO+FAT;5!+!08     !P ' .P!  #E:0     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>ea0206790-8k_abvcbio_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="abvc-20240524.xsd" xlink:type="simple"/>
    <context id="AsOf2024-05-24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
        </entity>
        <period>
            <startDate>2024-05-24</startDate>
            <endDate>2024-05-24</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <dei:AmendmentFlag contextRef="AsOf2024-05-24" id="Fact000003">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey contextRef="AsOf2024-05-24" id="Fact000004">0001173313</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="AsOf2024-05-24" id="Fact000009">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="AsOf2024-05-24" id="Fact000010">2024-05-24</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="AsOf2024-05-24" id="Fact000011">ABVC BIOPHARMA, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="AsOf2024-05-24" id="Fact000012">NV</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="AsOf2024-05-24" id="Fact000013">001-40700</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="AsOf2024-05-24" id="Fact000014">26-0014658</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="AsOf2024-05-24" id="Fact000015">44370 Old Warm Springs Blvd.</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="AsOf2024-05-24" id="Fact000016">Fremont</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="AsOf2024-05-24" id="Fact000017">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="AsOf2024-05-24" id="Fact000018">94538</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="AsOf2024-05-24" id="Fact000019">510</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="AsOf2024-05-24" id="Fact000020">668-0881</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="AsOf2024-05-24" id="Fact000021">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="AsOf2024-05-24" id="Fact000022">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="AsOf2024-05-24" id="Fact000023">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="AsOf2024-05-24" id="Fact000024">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="AsOf2024-05-24" id="Fact000025">Common Stock, par value $0.001 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="AsOf2024-05-24" id="Fact000026">ABVC</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="AsOf2024-05-24" id="Fact000027">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="AsOf2024-05-24" id="Fact000028">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
